(Q30438159)

English

Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Helper T-cell responses and clinical activity of a melanoma vaccine with multiple peptides from MAGE and melanocytic differentiation antigens (English)

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Craig Slingluff

1

object named as

Craig L Slingluff

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Kimberly A Chianese-Bullock

7

object named as

Kimberly A Chianese-Bullock

1 reference

Europe PubMed Central

18 August 2017

PMC publication ID

author name string

Gina R Petroni

2

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Walter Olson

3

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Andrea Czarkowski

4

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

William W Grosh

5

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Mark Smolkin

6

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Patrice Y Neese

8

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Donna H Deacon

9

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Carmel Nail

10

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Priscilla Merrill

11

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Robyn Fink

12

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

James W Patterson

13

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Patrice K Rehm

14

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

language of work or name

0 references

publication date

22 September 2008

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Journal of Clinical Oncology

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

26

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

30

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

4973-4980

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Immunity to melanoma antigens: from self-tolerance to immunotherapy

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652084

20 June 2018

Immunization of HLA-A*0201 and/or HLA-DPbeta1*04 patients with metastatic melanoma using epitopes from the NY-ESO-1 antigen

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652084

20 June 2018

Immune responses to a class II helper peptide epitope in patients with stage III/IV resected melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652084

20 June 2018

Preventing the spontaneous modification of an HLA-A2-restricted peptide at an N-terminal glutamine or an internal cysteine residue enhances peptide antigenicity

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652084

20 June 2018

Immunization of patients with metastatic melanoma using both class I- and class II-restricted peptides from melanoma-associated antigens

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652084

20 June 2018

Phase I trial of a melanoma vaccine with gp100(280-288) peptide and tetanus helper peptide in adjuvant: immunologic and clinical outcomes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652084

20 June 2018

Evaluation of peptide vaccine immunogenicity in draining lymph nodes and peripheral blood of melanoma patients.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652084

20 June 2018

Melan-A/MART-1(51-73) represents an immunogenic HLA-DR4-restricted epitope recognized by melanoma-reactive CD4(+) T cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652084

20 June 2018

Type 1 CD4(+) T-cell help is required for induction of antipeptide multispecific cytotoxic T lymphocytes by a lipopeptidic vaccine in rhesus macaques

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652084

20 June 2018

Melanoma cells present a MAGE-3 epitope to CD4(+) cytotoxic T cells in association with histocompatibility leukocyte antigen DR11.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652084

20 June 2018

Identification of MAGE-3 epitopes presented by HLA-DR molecules to CD4(+) T lymphocytes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652084

20 June 2018

The central role of CD4(+) T cells in the antitumor immune response

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652084

20 June 2018

Tumour-specific MHC-class-II-restricted responses after in vitro sensitization to synthetic peptides corresponding to gp100 and Annexin II eluted from melanoma cells.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652084

20 June 2018

CD4+ T cells from peripheral blood of a melanoma patient recognize peptides derived from nonmutated tyrosinase

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652084

20 June 2018

Isolation of novel HLA-DR restricted potential tumor-associated antigens from the melanoma cell line FM3.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652084

20 June 2018

Melanoma-specific CD4+ T cells recognize nonmutated HLA-DR-restricted tyrosinase epitopes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652084

20 June 2018

T-cell help for cytotoxic T lymphocytes is mediated by CD40-CD40L interactions

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=2652084

26 November 2018

A model for CD8+ CTL tumor immunosurveillance and regulation of tumor escape by CD4 T cells through an effect on quality of CTL

1 reference

https://pubmed.ncbi.nlm.nih.gov/18809608

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1200/JCO.2008.17.3161

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

18 August 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q30438159&oldid=1982947977"